CN105853999A - Interferon lambda-containing aerosol inhalant - Google Patents
Interferon lambda-containing aerosol inhalant Download PDFInfo
- Publication number
- CN105853999A CN105853999A CN201610258265.0A CN201610258265A CN105853999A CN 105853999 A CN105853999 A CN 105853999A CN 201610258265 A CN201610258265 A CN 201610258265A CN 105853999 A CN105853999 A CN 105853999A
- Authority
- CN
- China
- Prior art keywords
- atomized inhalation
- interferon
- interferon lambda
- pharmaceutically acceptable
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Abstract
The invention belongs to the field of preparations of biotechnology medicines, and relates to an interferon lambda-containing aerosol inhalant. The aerosol inhalant contains 1-1000 micrograms of interferon lambda and a right amount of pharmaceutical adjuvant of the aerosol inhalant in a single dosage of administration; preferentially, the aerosol inhalant contains 5-100 micrograms of interferon lambda and a right amount of pharmaceutical adjuvant of the aerosol inhalant in a single dosage of administration; more preferentially, the aerosol inhalant contains 10-50 micrograms of interferon lambda and a right amount of pharmaceutical adjuvant of the aerosol inhalant in a single dosage of administration. Compared with the traditional interferon alpha-containing aerosol inhalant, the interferon lambda-containing aerosol inhalant obviously improves the treatment effect when being used for treating viral pneumonia.
Description
Technical field
The present invention generally relates to respiratory tract and the formulation for pulmonary delivery of interferon, and the atomization in particular to interferon is inhaled
Enter agent.
Background technology
Viral pneumonia is the commonly encountered diseases in a kind of infant period, the life and health of serious harm infant.According to not exclusively
Statistics, the infant more than 90% infected viral pneumonia before 2 years old, and wherein more than 80% case is within 1 years old, morbidity
The peak age is 2-6 month, heavier case seen from 1-6 month.The death that infant causes because infecting viral pneumonia is in prosperity
Country is 0.5%-2.0%, in developing country up to 7%, at the first cause of China's Infant and child deaths especially.Additionally, it is sick
The infectiousness of toxicity pneumonia and again infectivity are very strong, have been reported that and show can occur between kinsfolk in succession to infect, and have infected baby children
Youngster in 10 years again infection rate be up to 65%.
The virus causing viral pneumonia is mainly adenovirus (adenovirus, ADV) and respiratory syncytial virus
(respiratory syncytial virus, RSV), next to that influenza virus (influenza virus, IFV) and parainfluenza
Virus (parainfluenza virus, PIV), is cytomegalovirus (cytomegalovirus, CMV), herpes simplex again
Virus (herpes simplex virus, HSV), enterovirus (enterovirus, EV), human metapneumovirus (hMPV) etc..
Owing to these viruses easily morph, after virus infects, easily induce further antibacterial in addition infect, thus give infant
Causing mixed infection and complication, therefore Infant Viral Pneumonia is difficulty with comprehensive special preventing and treating, lacks clinically and has
The Drug therapy of effect.
Chemicals is the main medicine treating viral pneumonia at present, and reason is that the Clinical practice time is the longest, can be fast
Speed is removed and is infected virus；But the shortcoming of chemotherapy viral pneumonia is that the state of an illness easily rebounds after drug withdrawal, it is impossible to regulation and
Raising children patient immunity is to antiviral, and easily produces drug resistance during life-time service.Clinical treatment is sick at present
The chemicals of toxicity pneumonia includes but not limited to ribavirin, ganciclovir, Oseltamivir, vidarabine, amantadine etc..
Such as United States Patent (USP) 5,290,540 discloses ribavirin for the method treating viral pneumonia.
Viral pneumonia is treated and is used increasingly extensive in research in recent years by Chinese medicine, and this gentleness coming from herbal nature is held
For a long time, and have immunoregulation effect concurrently, but the treatment by Chinese herbs viral pneumonia cycle is long, and Chinese medicine to a great extent and is unsuitable for
Infant uses, and additionally the long-term safety sex chromosome mosaicism of Chinese medicine is also a problem that can not be ignored.Have been reported that clinical research at present
Chinese medicine for viral pneumonia treatment includes but not limited to Folium Isatidis, Radix Isatidis, Flos Lonicerae, Fructus Forsythiae, Rhizoma Belamcandae, Radix Scutellariae, Rhizoma Coptidis, fiber crops
Huang, Semen Armeniacae Amarum etc..Such as Chinese patent application 03131642.5 discloses a kind of lung heat clearing treating infantile viral pneumonia and is administered orally
Liquid formulation, it is by Chinese herbal medicine such as Herba Ephedrae, Gypsum Fibrosum, Semen Armeniacae Amarum, Semen Lepidii (Semen Descurainiae), Cortex Mori, Radix Peucedani, Bombyx Batryticatus, Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati, Rhizoma Bistortaes
Composition.And for example Chinese patent application 02138175.5 discloses a kind of pharmaceutical composition treating infantile viral pneumonia, its by
Herba Ephedrae, Semen Armeniacae Amarum, Gypsum Fibrosum, Radix Glycyrrhizae, Radix Peucedani, Bombyx Batryticatus, Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati, Rhizoma Bistortae, Semen Lepidii (Semen Descurainiae), Cortex Mori ten a herb composition.
Along with the fast development of biotech drug, increasing research in recent years pays close attention to biotech drug to disease
The treatment of toxicity pneumonia, the biotech drug wherein used includes but not limited to interferon, interleukin, third kind of ball of human blood
Albumen, thymosin, specific antiviral antibody etc., the report especially used with interferon is most.Such as Chinese patent application
03147580.9 discloses a kind of recombinant human interferon alpha nebula treating viral pneumonia, and it is by recombinant human interferon-alpha stock solution
Being equipped with suitable protective agent, mucosa absorption accelerator, antibacterial etc. to make, pH value is at 5.0-8.0.
Interferon (interferon, IFN) is a kind of initially to be had concurrently antiviral, antiproliferative by what animal body produced and exempted from
The cytokine protein class medicine of epidemic disease regulation effect, the difference according to its generating unit, the mechanism of action, pharmacodynamic profile etc. is permissible
It is divided into tri-kinds of big types of I, II, III.Wherein I type interferon is primarily referred to as interferon-ALPHA and interferon beta, and interferon-ALPHA has again bag
Include Interferon a2a, interferon alpha 2 b, Interferon α1 b at the interior native subtypes more than 20 kinds；II type interferon is primarily referred to as doing
Disturb element γ；Type iii interferon is primarily referred to as interferon lambda, including interferon lambda 1, interferon lambda 2,3 three kinds of native subtypes of interferon lambda.
Biotech drug, especially interferon are suffered from for the treatment of viral pneumonia, persistent, scalable and raising
Youngster's immunity of organisms, to antiviral, is not likely to produce drug resistance, and safety is higher.But at present in interferon therapy viral pneumonia
In report, used is all interferon-ALPHA, there are no the report of use type iii interferon, i.e. interferon lambda.
Compared to I, II type interferon, the discovery of type iii interferon is later with report.Wherein interferon lambda 1 is the earliest by Tianjin not
Ji Nidi Ces Co., Ltd be disclosed in its International Patent Application PCT/US2001/021087 (January 10 2002 international publication day,
Entering the national applications number after National Phase in China is 01813153.0) in, interferon lambda 2 and interferon lambda 3 are the most also by these public affairs
Department is disclosed in its International Patent Application PCT/US2002/012887, and (October 31 2002 international publication day enters China national
National applications number after stage is 02801970.9) in.And the said firm again after International Patent Application PCT/US2004/
025864 (on March 17 2005 international publication day, entering the national applications number after National Phase in China is
200480029170.7) then interferon lambda and multiple variant thereof have been done in the combing of system, interferon lambda 1, λ 2, the aminoacid of λ 3
What sequence was determined respectively has been reported in SEQ ID No.4 disclosed in its description, SEQ ID No.2 and SEQ ID No.6,
Interferon lambda 1, λ 2, the preparation method of λ 3 have then been reported in its description embodiment 1-9 (additionally, interferon lambda 1, λ 2, λ 3
Preparation method also can be found in International Patent Application PCT/US2002/012887, the i.e. explanation of Chinese patent application 02801970.9
Book embodiment 1-7).
The interferon lambda 1 code name when the openest is zcyto21, and the interferon lambda 2 code name when the openest is
Zcyto20, the interferon lambda 3 code name when the openest is zcyto22.In research subsequently because it is found that their gene,
With IL-10 (IL-10) closely, therefore they are attributed to IL-10 family to tertiary protein structure, respectively by again
Named IL-29, IL-28A and IL-28B.
Although zcyto21, zcyto20 only have 17% with the Amino acid sequence identity (namely homology) of interferon-ALPHA, with
The Amino acid sequence identity of interferon beta only has 14%, only has 4% with the Amino acid sequence identity of interferon gamma；zcyto22
Only have 16% with the Amino acid sequence identity of interferon-ALPHA, only have 13% with the Amino acid sequence identity of interferon beta, with dry
The Amino acid sequence identity disturbing element γ only has 4%, but they have been found that in research subsequently and confirm and traditional interference
Have similar signal transduction pathway, have a lot of interferoid character.Therefore from the angle of function, they the most respectively by
Named interferon lambda 1, interferon lambda 2 and interferon lambda 3.
In view of the curative effect of viral pneumonia is also needed to be improved further by traditional interferon-ALPHA, therefore, it is necessary to attempt
Type iii interferon, i.e. interferon lambda are for the treatment of viral pneumonia.
And in terms of the drug delivery system for the treatment of viral pneumonia, atomized inhalation is that one is sent out the most clinically
The new form of administration that exhibition is got up.So-called atomized inhalation, refers to through atomization, medicinal liquid is become medicine mist, reaches breathing system through sucking
System target site plays the dosage form of therapeutical effect.The administration of atomized inhalation must be by certain nebulization equipment, including compression
Nebulizer, ultrasound atomizer etc..Respiratory disease portion is can be done directly on without absorption after being administered due to atomized inhalation
Position, thus compare other dosage forms and have considerably higher bioavailability and drug effect, therefore atomized inhalation has been increasingly becoming clinic
The first-selected dosage form of upper treatment infantile viral pneumonia.
Summary of the invention
The primary and foremost purpose of the present invention is to provide the atomized inhalation of a kind of interferon lambda, for Infant Viral Pneumonia
Treatment, improve curative effect further.
In the embodiment on basis, the atomized inhalation unit dosage form of the interferon lambda of the present invention is (such as
0.25ml, 0.5ml, 1ml, 2ml, 3ml, 4ml or 5ml) in the atomized inhalation of interferon lambda and Sq containing 1-1000 μ g
Pharmaceutically acceptable auxiliaries.
Described atomized inhalation pharmaceutically acceptable auxiliaries is including, but not limited to interferon lambda activity protecting agent, osmotic pressure regulation
One or more in agent, preservative, adsorption inhibitor, pH stable regulation agent.And it should be pointed out that, that one or a class material can
The effect of multiple pharmaceutically acceptable auxiliaries function can be simultaneously worked as.Such as human serum albumin can simultaneously work as osmotic pressure regulator, work
Property protective agent, the effect of adsorption inhibitor.
Interferon lambda activity protecting agent plays protection interferon lambda atomized inhalation and lives in preparing, transport, store and using
Property is not lost or the effect of less forfeiture, can also select aminoacid, polyhydric alcohol, cyclodextrin, ovum phosphorus in addition to human serum albumin
The combination of one or more in the materials such as fat.
Osmotic pressure regulator plays and is adjusted to and blood of human body substantially isotonic by the osmotic pressure of interferon lambda atomized inhalation
(240-360mOsm/L) effect, can be with in the materials such as selective chlorination sodium, mannitol, glucose in addition to human serum albumin
The combination of one or more.
Preservative play interferon lambda atomized inhalation preparation, transport, store and use during suppress microorganism raw
Long, especially harmful microorganism growth, and it is dry to prevent microorganism and metabolite thereof from destroying ingredient, particularly active component
Disturb the effect of element λ.Such preservative may select benzalkonium chloride, benzalkonium bromide, benzyl alcohol, phenol, cresol (include again adjacent first
Phenol, metacresol, paracresol), (i.e. p-Hydroxybenzoate, including methyl parahydroxybenzoate, ethyl ester, propyl ester, fourth for Nipagin ester
Ester etc.) etc. the combination of one or more in material.
Adsorption inhibitor plays suppression or reduce and contains the container of interferon lambda atomized inhalation to interferon lambda and other are auxiliary
The effect of absorption of material, can also select surfactant in addition to human serum albumin, in surfactant the most non-from
Sub-surface activating agent, and more preferably Tweens nonionic surfactant.
PH stable regulation agent is played stable for the pH of the interferon lambda atomized inhalation work at physiology appropriate pH (5.0-8.0)
With, and requiring physiological safety, selectable scope is molten including, but not limited to phosphate buffered solution system, citrate buffering
Liquid system, Ascorbate buffer solution system, preferably phosphate buffer solution system.Such pH stable regulation agent the denseest
Degree should be between 0.1-500mmol/L, preferably between 1-100mmol/L, and more preferably between 5-20mmol/L.
First the interferon lambda atomized inhalation of the present invention should dissolve each pharmaceutically acceptable auxiliary by preparation aequum in process for preparation
Material, then after mixing homogeneously with the stock solution of interferon lambda the volume of water use regulation solution to target dose volume.Each pharmaceutically acceptable auxiliary
The dissolving of material can be carried out simultaneously, it is possible to carry out respectively, but the preparation of slightly solubility pharmaceutically acceptable auxiliaries should individually be carried out, and optionally add
Heat and/or add certain cosolvent.Course of dissolution should quickly mix, note avoiding the drastically change of pH, temperature etc., thus
Cause bioinactivation and/or the chemical degradation of active constituents of medicine interferon lambda.
In a preferred embodiment, the atomized inhalation unit dosage form of the interferon lambda of the present invention is (such as
0.25ml, 0.5ml, 1ml, 2ml, 3ml, 4ml or 5ml) in the atomized inhalation of interferon lambda and Sq containing 5-100 μ g
Pharmaceutically acceptable auxiliaries.
In a preferred embodiment, the atomized inhalation unit dosage form of the interferon lambda of the present invention is (such as
0.25ml, 0.5ml, 1ml, 2ml, 3ml, 4ml or 5ml) in the atomized inhalation of interferon lambda and Sq containing 10-50 μ g
Pharmaceutically acceptable auxiliaries.
In a preferred embodiment, the interferon lambda in the atomized inhalation of the interferon lambda of the present invention is interferon
A kind of in λ 1, interferon lambda 2, interferon lambda 3 or several with arbitrary proportion mixing.
In a preferred embodiment, the interferon lambda in the atomized inhalation of the interferon lambda of the present invention is interferon
λ1。
In a preferred embodiment, the atomized inhalation pharmaceutically acceptable auxiliaries of the present invention comprises interferon lambda activity guarantor
Protect agent, the combination of one or more in human serum albumin, aminoacid, polyhydric alcohol, cyclodextrin, lecithin matter.
In a preferred embodiment, the atomized inhalation pharmaceutically acceptable auxiliaries of the present invention comprises osmotic pressure regulator,
The combination of one or more in human serum albumin, NaCl, mannitol, glucose.
In a preferred embodiment, the atomized inhalation pharmaceutically acceptable auxiliaries of the present invention comprises preservative, selected from benzene
Prick the combination of one or more in oronain, benzalkonium bromide, benzyl alcohol, phenol, cresol, Nipagin ester.
In a preferred embodiment, the atomized inhalation pharmaceutically acceptable auxiliaries of the present invention comprises adsorption inhibitor, choosing
The combination of one or more in human serum albumin and surfactant.
In a preferred embodiment, comprise can be by atomized inhalation for the atomized inhalation pharmaceutically acceptable auxiliaries of the present invention
The stable buffer solution system in the range of 5.0-8.0 of pH, selected from phosphate buffered solution system, citrate buffer solution
The combination of one or more in system, Ascorbate buffer solution system.
In a preferred embodiment, the atomized inhalation of the interferon of the present invention contains: 1) unit dosage form
The interferon lambda of 1-1000 μ g in (such as 0.25ml, 0.5ml, 1ml, 2ml, 3ml, 4ml or 5ml)；2) human blood of 1-50mg/ml
Pure albumen；3) NaCl of 1-8mg/ml；4) disodium hydrogen phosphate-sodium dihydrogen phosphate of 1-100mmol/L, pH7.0 solution.
In a preferred embodiment, the atomized inhalation of the interferon of the present invention contains: 1) unit dosage form
The interferon lambda of 5-100 μ g in (such as 0.25ml, 0.5ml, 1ml, 2ml, 3ml, 4ml or 5ml)；2) human serum of 5-30mg/ml
Albumin；3) NaCl of 2-7mg/ml；4) disodium hydrogen phosphate-sodium dihydrogen phosphate of 5-50mmol/L, pH7.0 solution.
In a preferred embodiment, the atomized inhalation of the interferon of the present invention contains: 1) unit dosage form
The interferon lambda of 10-50 μ g in (such as 0.25ml, 0.5ml, 1ml, 2ml, 3ml, 4ml or 5ml)；2) human blood of 10-20mg/ml
Pure albumen；3) NaCl of 4-6mg/ml；4) disodium hydrogen phosphate-sodium dihydrogen phosphate of 10-20mmol/L, pH7.0 solution.
It is a further object to provide the atomized inhalation of interferon lambda in preparation treatment viral pneumonia medicine
Application.Utilize the atomized inhalation treatment viral pneumonia of the interferon lambda of drug content of the present invention, can obtain the most preferably
Therapeutic effect.
The term " interferon lambda " used in the present invention or " Lambda interferon " include that human body or animal body are at extraneous pathogenicity thing
Matter stimulates the lower natural antiviral activity material (including interferon lambda 1, interferon lambda 2, interferon lambda 3) produced, and also includes passing through base
Because engineering method selects the recombinant molecule identical with above-mentioned native sequences of suitable expression vector expression, also include interference
In element λ 1, interferon lambda 2, the mutant of interferon lambda 3, the especially description of International Patent Application PCT/US2004/025864
Clearly mention or even the mutant of interferon lambda of open aminoacid sequence.
The term " therapeutically effective amount " used in the present invention represents when using active constituents of medicine for treating or preventing disease
Time sick, the amount of active constituents of medicine be enough to realize the treatment to disease or prevention.Therapeutically effective amount will be according to active constituents of medicine, disease
Sick and its seriousness and the age of treated patient, body weight etc. and different.
The term " atomized inhalation pharmaceutically acceptable auxiliaries " used in the present invention refers to when atomized inhalation Formulation, for
Solve the problems such as the dissolubility of atomized inhalation, effectiveness, stability, safety, join removing in atomized inhalation prescription
Beyond active constituents of medicine, self is to human body or other auxiliary elements of animal body safety.
Detailed description of the invention
By examples below, the enforcement of the present invention is described further, but embodiments of the present invention are not limited to
In examples below.
Embodiment 1: the preparation of interferon atomized inhalation
By the atomized inhalation preparing interferon such as the method for table 1 below.Wherein " PB " is disodium hydrogen phosphate-sodium dihydrogen phosphate
Buffer solution (pH7.0).
The preparation of table 1 interferon atomized inhalation
Embodiment 2: the animal experiment of interferon atomized inhalation treatment viral pneumonia
1) RSV Virus culture
Respiratory syncytial virus type strain RSV-Long (quoted from Beijing institute of pediatrics) is inoculated on Hep-2 cell,
Results when cytopathy reaches more than 80%, by frozen for virus liquid in liquid nitrogen, the used time, 1000rpm was centrifuged 10 in 37 DEG C of thawings
Minute, take supernatant standby.
2) foundation of RSV mouse nuclei
Taking the Balb/c mice of 126 6-7 week old, male and female half and half, after being all anesthetized with ether, via intranasal application instills respectively
106PFU/ml RSV virus liquid 0.1ml, drips virus every day 1 time, drips altogether 2 times, and within the 3rd day, mice perpendicular hair, dysphoria occurs, exhales
Inhale rapid, abdominal muscle tic positive reaction, show the success of rsv infection Establishment of mouse model.
3) it is grouped and is administered
Above-mentioned 126 mices are randomly divided into 21 groups, often group 6, male and female half and half.Group 1 is to group 20 ultrasonic mist every day respectively
Change and suck each 1ml of atomized inhalation 1 to atomized inhalation 20 described in previous embodiment (after addition normal saline dilution to 4ml
Neulized inhalation)；Organize 21 every day Ultrasonic atomising taring normal saline 4ml.All each group of the most average daily Ultrasonic atomising taring 1 time, altogether
Ultrasonic atomising taring 5 times (5 days).Taking Mouse Blood after 5 days and carry out BALF numeration of leukocyte, the average result of 6 mices of each group is such as
Shown in table 2 below.
Table 2 BALF numeration of leukocyte result
Claims (10)
1. the atomized inhalation of interferon lambda, is characterized in that the interferon lambda containing 1-1000 μ g and Sq in unit dosage form
Atomized inhalation pharmaceutically acceptable auxiliaries.
Atomized inhalation the most according to claim 1, is characterized in that the interferon containing 5-100 μ g in unit dosage form
λ and the atomized inhalation pharmaceutically acceptable auxiliaries of Sq.
Atomized inhalation the most according to claim 2, is characterized in that the interferon containing 10-50 μ g in unit dosage form
λ and the atomized inhalation pharmaceutically acceptable auxiliaries of Sq.
Atomized inhalation the most according to claim 1, is characterized in that described atomized inhalation pharmaceutically acceptable auxiliaries comprises dry
Disturb element λ activity protecting agent, one in human serum albumin, aminoacid, polyhydric alcohol, cyclodextrin, lecithin matter or
Several combinations.
Atomized inhalation the most according to claim 1, is characterized in that described atomized inhalation pharmaceutically acceptable auxiliaries comprises and oozes
Thoroughly press regulator, the combination of one or more in human serum albumin, NaCl, mannitol, glucose.
Atomized inhalation the most according to claim 1, is characterized in that described atomized inhalation pharmaceutically acceptable auxiliaries comprises anti-
Rotten agent, the combination of one or more in benzalkonium chloride, benzalkonium bromide, benzyl alcohol, phenol, cresol, Nipagin ester.
Atomized inhalation the most according to claim 1, is characterized in that described atomized inhalation pharmaceutically acceptable auxiliaries comprises energy
By stable for the pH of the atomized inhalation buffer solution system in the range of 5.0-8.0, selected from phosphate buffered solution system, citron
The combination of one or more in hydrochlorate buffer solution system, Ascorbate buffer solution system.
Atomized inhalation the most according to claim 1, it is characterized in that described interferon lambda be interferon lambda 1, interferon lambda 2,
A kind of in interferon lambda 3 or several with arbitrary proportion mixing.
Atomized inhalation the most according to claim 8, is characterized in that described interferon lambda is interferon lambda 1.
10. according to the atomized inhalation one of claim 1-9 Suo Shu preparation treatment viral pneumonia medicine in application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610258265.0A CN105853999A (en) | 2016-04-22 | 2016-04-22 | Interferon lambda-containing aerosol inhalant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610258265.0A CN105853999A (en) | 2016-04-22 | 2016-04-22 | Interferon lambda-containing aerosol inhalant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105853999A true CN105853999A (en) | 2016-08-17 |
Family
ID=56633892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610258265.0A Pending CN105853999A (en) | 2016-04-22 | 2016-04-22 | Interferon lambda-containing aerosol inhalant |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105853999A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113491807A (en) * | 2020-04-03 | 2021-10-12 | 深圳麦克韦尔科技有限公司 | Aerosol generating device |
| CN114053397A (en) * | 2022-01-17 | 2022-02-18 | 北京三元基因药业股份有限公司 | Stable interferon multi-dose injection and preparation method thereof |
| CN114533706A (en) * | 2022-02-15 | 2022-05-27 | 深圳市利云德生物技术有限公司 | Aerosol inhalation preparation for preventing and treating respiratory diseases and application thereof |
| CN115531315A (en) * | 2022-12-05 | 2022-12-30 | 上海惠盾因泰生物科技有限公司 | Recombinant human interferon lambda 1 nasal spray and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365474A (en) * | 2005-09-09 | 2009-02-11 | 帝国创新有限公司 | Interferon lambda therapy for treatment of respiratory diseases |
| CN102716469A (en) * | 2012-07-07 | 2012-10-10 | 北京三元基因工程有限公司 | Dry powder inhalant of interferon alpha |
| CN102716105A (en) * | 2012-07-07 | 2012-10-10 | 北京三元基因工程有限公司 | Dry powder inhalant of interferon Alpha |
-
2016
- 2016-04-22 CN CN201610258265.0A patent/CN105853999A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365474A (en) * | 2005-09-09 | 2009-02-11 | 帝国创新有限公司 | Interferon lambda therapy for treatment of respiratory diseases |
| CN102716469A (en) * | 2012-07-07 | 2012-10-10 | 北京三元基因工程有限公司 | Dry powder inhalant of interferon alpha |
| CN102716105A (en) * | 2012-07-07 | 2012-10-10 | 北京三元基因工程有限公司 | Dry powder inhalant of interferon Alpha |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113491807A (en) * | 2020-04-03 | 2021-10-12 | 深圳麦克韦尔科技有限公司 | Aerosol generating device |
| CN113491807B (en) * | 2020-04-03 | 2023-07-28 | 深圳麦克韦尔科技有限公司 | Aerosol generating device |
| CN114053397A (en) * | 2022-01-17 | 2022-02-18 | 北京三元基因药业股份有限公司 | Stable interferon multi-dose injection and preparation method thereof |
| CN114533706A (en) * | 2022-02-15 | 2022-05-27 | 深圳市利云德生物技术有限公司 | Aerosol inhalation preparation for preventing and treating respiratory diseases and application thereof |
| CN114533706B (en) * | 2022-02-15 | 2022-10-14 | 深圳市利云德生物技术有限公司 | Aerosol inhalation preparation for preventing and treating respiratory diseases and application thereof |
| CN115531315A (en) * | 2022-12-05 | 2022-12-30 | 上海惠盾因泰生物科技有限公司 | Recombinant human interferon lambda 1 nasal spray and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105853999A (en) | Interferon lambda-containing aerosol inhalant | |
| CN106668832B (en) | Application of polypeptide in preparation of medicine for treating enterovirus infection | |
| CN105920586A (en) | Interferon aerosol propellant | |
| CN111346219A (en) | Use of interferon in preparing medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection | |
| CN112791097A (en) | Application of iodine in preparing medicament for preventing and treating respiratory infectious diseases and method for preparing low-particle-size iodine-containing aerosol | |
| CN102716105B (en) | Dry powder inhalant of interferon Alpha | |
| WO2015027848A1 (en) | Method of administering formulation comprising peramivir and/or derivative thereof | |
| CN105816857A (en) | Aqueous solution preparation of interferon (IFN) | |
| CN105770862A (en) | Dry powder inhaler of interferon | |
| CN107789556A (en) | A kind of Juhong Tanke Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
| Nainwal | Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities | |
| CN102416167B (en) | Aerosol inhalant containing interferon alpha and terbutaline sulfate | |
| EP4218726A1 (en) | Composition for inhibiting respiratory virus and respiratory virus prevention and treatment method | |
| CN102416168B (en) | Aerosol inhalant containing interferon alpha and ambroxol | |
| CN102430112B (en) | Atomization inhalant prepared from interferon alpha and salbutamol sulfate | |
| CN103690934B (en) | Aerosol inhalation agent of interferon alpha and budesonide | |
| CN100417388C (en) | Compound injection preparation containing ligustrazine and breviscapine and its preparation method | |
| CN104667263B (en) | The atomized inhalation of interferon-' alpha ' and budesonide | |
| CN103721244B (en) | Atomization inhalant containing interferon-alpha and gentamicin sulfate | |
| CN112999204A (en) | Shuanghuanglian aerosol inhalation solution preparation and preparation method thereof | |
| CN102416166B (en) | Aerosol inhalant containing interferon alpha and ipratropium bromide | |
| CN102552440A (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN102416165B (en) | Aerosol inhalation agent containing interferon alpha and dexamethasone sodium phosphate | |
| CN107648249B (en) | Application of the desgalactotigonin in the drug for preparing prevention influenza infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160817 |
|
| RJ01 | Rejection of invention patent application after publication |